

## Disposition of Participants

	Placebo		Xanomeline Low Dose		Xanomeline High Dose	
	n	(%)	n	(%)	n	(%)
Participants in population	86		84		84	
Completed	58	(67.4%)	25	(29.8%)	27	(32.1%)
Discontinued	28	(32.6%)	59	(70.2%)	57	(67.9%)
Adverse Event	8	(9.3%)	44	(52.4%)	40	(47.6%)
Death	2	(2.3%)	1	(1.2%)	0	(0.0%)
I/E Not Met	1	(1.2%)	0	(0.0%)	2	(2.4%)
Lack of Efficacy	3	(3.5%)	0	(0.0%)	1	(1.2%)
Lost to Follow-up	1	(1.2%)	1	(1.2%)	0	(0.0%)
Physician Decision	1	(1.2%)	0	(0.0%)	2	(2.4%)
Protocol Violation	1	(1.2%)	1	(1.2%)	1	(1.2%)
Sponsor Decision	2	(2.3%)	2	(2.4%)	3	(3.6%)
Withdrew Consent	9	(10.5%)	10	(11.9%)	8	(9.5%)

Source: ADSL dataset